Introduction
The myocardium responds to acute ischaemic insult through activating proangiogenic signalling pathways that promote the formation of new capillaries, arterioles, and collateral vessels to feed the affected tissues, thus limiting the extent of myocardial damage. However, this repair process is impaired in people with diabetes, resulting in a marked diminution of cardiac function following an ischaemic insult. 1, 2 The existence of subclinical diabetic heart disease (DHD) 3 is considered to be one of the major causes of this impairment. While DHD was once thought to be mainly due to macrovascular damage, there is a growing body of evidence suggesting that diabetes also induces microvascular disease, commonly referred to as diabetic microangiopathy. 1, 4 Mounting evidence from the past two decades has demonstrated that diabetesinduced microvascular abnormalities in the heart can alter cardiac function and structure. In addition, several clinical and pre-clinical animal studies have confirmed regression of the microvasculature in the diabetic heart. 2, 4, 5 Endothelial dysfunction precedes vascular damage in diabetes and is mainly due to the altered gene expression of several angiogenic and vascular growth factors in the vasculature; however, the precise molecular mechanism leading to endothelial dysfunction in the diabetic heart is still unclear. This is critical because recent studies have shown that molecular alterations in diabetic cardiomyocytes develop at a very early stage of diabetes and form the basis for the development of contractile dysfunction in the later stages. 6, 7 Hence, the identification of molecular regulators of endothelial function in the diabetic heart will provide new insights into the pathogenesis of disease and opportunities for the development of potential treatment options for diabetic patients with cardiovascular complications. MicroRNAs (miRs) are gaining interest as key regulators in the pathophysiology of cardiovascular disease (CVD). 3 Reports from pre-clinical animal models as well as recent clinical trials have shown that modulating miR expression using specific miR mimics or inhibitors may have beneficial effects in a wide variety of diseases. 3 Endothelial cellenriched miR-126 and miR-132, also known as angiomiRs, have recently been studied for their role in endothelial dysfunction, angiogenesis, and CVD. 8, 9 Here, we demonstrate the dysregulation of circulating miR-126 and miR-132 from the very early stages in people with type 2 diabetes without known CVD. We also show the marked dysregulation of both miRs in the human diabetic myocardium. Moreover, using a mouse model of type 2 diabetes, we confirm that the dysregulation of both miRs precedes the development of microangiopathy in the heart. Finally, we demonstrate that the normalization of miR-126 and miR-132 in ex vivo diabetic aortic rings and in vitro high glucose (HG)-treated human umbilical vein endothelial cells (HUVEC) restored their angiogenic potential.
Methods
A detailed description of the experimental procedure and statistical analysis is provided in the supplementary electronic file.
Ethics
The Health and Disability Ethics Committee of New Zealand and the Human Ethics Committee of the University of Otago, New Zealand approved the human myocardium study. All of the patients gave written informed consent for the collection and use of their samples in this study. The Animal Ethics Committee of the University of Otago, New Zealand approved the animal study.
Human plasma sample collection
Peripheral blood samples were collected from people with type 2 diabetes without any known history of CVD; these were grouped according to different durations of diabetes (1-5, 6-10, 11-15, 16-20 , and > 20 years after diagnosis of diabetes, n = 8-12 at each time point). Age-and gender-matched non-diabetic healthy volunteers served as controls. Collection and use of the human samples conformed to the Declaration of Helsinki.
Human myocardial tissue collection
Right atrial appendage (RAA) and epicardial left ventricular (LV) biopsies were collected from type 2 diabetic (D-IHD) (n = 10, HbA1c 56 ± 8 mMol/ L) and non-diabetic (ND-IHD) (n = 10, HbA1c 38 ± 5 mMol/L, P < 0.001 vs. diabetic) patients with preserved ejection fraction (EF) (54.27 ± 8.4% in diabetics vs. 58.42 ± 7.1% in non-diabetics) undergoing on-pump coronary artery bypass graft surgery. Myocardial tissue samples from non-diabetic non-IHD (ND-H, n = 8) were collected from cadavers without any known history of ischemic heart disease (IHD). Collection and use of the human samples conformed to the Declaration of Helsinki.
Animal model of type 2 diabetes
BKS.Cg-mþ/þLeprdb/J mice (db/db) and their non-diabetic C57BL/ksJleprþ littermates (db/þ) were used for the study. Under terminal anaesthesia (2,2,2, tribromoethanol, 640 mg/kg intraperitoneal injection), myocardial tissue samples were collected from both groups at seven different time points (8, 12, 16, 20, 24, 28 , and 32 weeks of age, n = 10 each). Immediately after excision, the hearts were either snap frozen in liquid nitrogen for molecular analyses or fixed in 4% paraformaldehyde solution for histological analysis. All of the animal experiments conformed to National Institute of Health (NIH) guidelines ('Guide for the Care and Use of Laboratory Animals') or the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.
Molecular analyses
7.1 RNA isolation and custom Taqman V R array miRNA cards Total RNA was isolated from plasma samples or snap-frozen cardiac tissues using the QIAGEN miRNeasy V R Mini Kit as per the manufacturer's instructions. 10 Cardiac-enriched miR expression profiling (Supplementary material online, Table S1 ) was carried out using custom Taqman V R Array miRNA Cards (Applied Biosystems).
Quantitative real-time RT-PCR analysis
Twenty nanograms of plasma/tissue-derived total RNA were reversetranscribed using an miR-126-and miR-132-specific stem loop structure and reverse transcription primers (Life Technologies) followed by amplification as described in our earlier studies. 11 
Luciferase reporter assay
HEK 293 cells were co-transfected with a pEZX-MT06 miR reporter vector construct (GeneCopoeia, Rockville, MD) containing 3'-untranslated region (3'UTR) of Spred1 and p120RasGAP and with miR-126 or miR-132 mimics or miR mimic negative controls or with empty luciferase reporter vector for 48 h. Luciferase activity was measured in cell lysates 48 h after transfection.
Western blot analysis
Cardiac tissues were homogenized in an ice-cold RIPA buffer; proteins were resolved by SDS-PAGE and transferred onto PVDF membrane. Membranes were probed with rabbit anti-VEGF (1:500 dilution), mouse anti-p120RasGAP (1:200 dilution), and mouse anti-b-actin (1:1000 dilution), all of which were acquired from Santa Cruz Biotechnology.
Immunofluorescence analysis
Five-micrometer-thick cryostat sections were probed with biotinconjugated Isolectin-B4 (B-1205, 1:100, Vector Laboratories) to visualize capillaries and with CY-3 conjugated anti-mouse a-smooth muscle actin (C6198) (Sigma Life Sciences; 1:400 for 3 h at RT) to visualize arterioles. Nuclei were visualized with DAPI (Santa Cruz Biotechnology TM : SC3598, 1:1000 for 3 min). 
Aortic ring assay
Aortic rings from 20-week-old diabetic-and age-matched non-diabetic littermates were used to study the therapeutic effects of miR-126 and miR-132 on endothelial sprouting following the previously published protocol. 12 
In vitro cell culture and HG experiments
HUVECs were purchased from Lonza and cultured as per the manufacturer's protocol. Four different batches of cells at 5th to 6th passages in the actively growing conditions were used for all of the experiments. The cells were used to quantify the effect of HG on cell proliferation (CYQUANT), apoptotic cell death (caspase-3/7 activity), and in vitro angiogenesis (matrigel tube formation and transwell migration assay).
Statistical analysis
All of the data are expressed as mean ± SEM. Comparison of multiple groups at different time points was performed by one-or two-way analysis of variance (ANOVA) with Holm-Sidak's or Bonferroni adjustment, respectively. Two-group analysis was performed by Student's t-test. A probability value (P) of less than 0.05 was considered to be statistically significant.
Results

Down-regulation of angiomiRs in the human diabetic heart
Our first aim was to identify the cardiovascular miRs involved in the pathogenesis of endothelial dysfunction in DHD. A customized Taqman V R array miR card was designed in order to study the expression of cardiovascular miRs that were known to be involved in the pathogenesis of various CVDs. 13 The study population included type 2 diabetic patients (D-IHD) and age-, gender-, and disease-matched non-diabetic patients (ND-IHD, n = 7 for both groups) undergoing on-pump coronary artery bypass graft surgery. Taqman V R Array miR Cards analysis using total RNA isolated from the RAA tissue showed marked changes in the expression level of 11 miRs (out of a total of 14 that were analysed) in the diabetic heart. Among the four endothelial cell-enriched miRs, only miR-126 and miR-132 showed significant down-regulation in the diabetic heart, whereas miR-92a and miR-320 were comparable to the nondiabetic heart ( Figure 1A and Supplementary material online, Table S1 ). Included in the other nine differentially expressed miRs were the miRs involved in the regulation of cardiac function (miR-1, miR-30a, miR-27a, and miR-208), cardiomyocyte apoptosis (miR-499 and miR-34a), fibrosis (miR-21 and miR-29b), and hypertrophy (miR-133) ( Figure 1A and Supplementary material online, Table S1 ). MiR-206 was undetectable in both the non-diabetic and diabetic samples ( Figure 1A and Supplementary material online, Table S1 ). Of note is that there was no significant change in the expression level of internal control U6 (Supplementary material online, Figure S1 ). Since the main focus of this study is to identify and demonstrate the role of miRs associated with endothelial dysfunction in the diabetic heart, we next focused on exploring the consequences of down-regulation of two major angiomiRs (miR-126 and miR-132), which we found to be significantly down-regulated in the diabetic heart ( Figure 1A and Supplementary material online, Table To eliminate the effect of ischemia on miR expression, non-diabetic healthy heart (ND-H) were used as controls. All data are expressed as Mean ± SEM. ***P < 0.001 and ****P < 0.0001 vs. ND-H; and dd P < 0.01 and ddd P < 0.001 vs. corresponding ND-IHD group by one-way ANOVA. n = 8 in all the groups except in ND-H (n = 5). S1) but still remain unexplored in the field. While our recent study demonstrated the down-regulation of miR-126 11 in human RAA and LV tissues, it is still not known whether the miR dysregulation precedes the development of any morphological changes in the heart. Moreover, one of the limitations of the previous study design and the design for miR card analysis was the presence of IHD in both diabetic and non-diabetic patients. Although both groups were matched for disease type, it is well known that IHD alone can adversely affect the miR expression pattern.
14 Hence, it was essential to include a group without IHD in order to exclude the changes in miR expression due to ischaemia. Therefore, for the other experiments on human hearts, we included myocardial samples collected from cadaveric hearts of similar age groups but without any known history of IHD (ND-H).
Using quantitative RT-PCR analysis, we further validated the downregulation of miR-132 in both RAA (P < 0.01, Figure 1B ) and LV (P < 0.001, Figure 1B ) tissues from the diabetic heart (P < 0.0001 vs. ND-IHD, Figure 1B ). While ischaemia alone (ND-IHD) significantly downregulated the expression level of miR-132 (P < 0.05 vs. ND-H), it was clearly evident that diabetes further diminished the expression of miR-132 ( Figure 1B) , thereby demonstrating the independent effect of diabetes on angiomiRs.
Increased microangiopathy in the human diabetic heart
To understand if the down-regulation of angiomiRs was associated with microangiopathy in the diabetic heart, we measured capillary and arteriole density, the established indicators of microangiopathy. 15 As ex- Figure 2B ).
To determine whether a reduced number of capillaries and arterioles was a consequence of increased endothelial cell death, we measured the prevalence of apoptosis in endothelial cells. As shown in Figure 2C , there was a significant increase in the number of TUNEL-positive endothelial cells in the diabetic heart (P < 0.05 vs. ND-IHD). Together, these findings demonstrate impaired angiogenesis, vasculogenesis, and endothelial cell death, confirming the prevalence of microangiopathy in the human diabetic heart.
Down-regulation of miR-126 and miR-132 precedes microangiopathy in the diabetic heart
Our next question was whether the dysregulation of angiomiRs preceded the development of microangiopathy in the diabetic heart. Preliminary observational data in human subjects suggested marked down-regulation in the circulating levels of both these angiomiRs in the plasma samples of type 2 diabetics from the early stages of diabetes compared to the agematched non-diabetics ( Figure 3A) . Importantly, these subjects had no history of CVD. However, due to the non-cardiovascular-specific nature of both miRs, 16, 17 it was essential to precisely determine if similar changes occurred in the diabetic heart before the development of cardiac dysfunction. Since this was not feasible in the observational human study, we used a well-characterized mouse model of type 2 diabetes. 18, 19 Consistent with our human study, quantitative RT-PCR analysis of RNA samples collected from obese type 2 diabetic mice (D) and age-and gender-matched lean non-diabetic mice (ND) hearts showed a dysregulated expression pattern of both miR-126 and miR-132 from the early stages of diabetes. Interestingly, the diabetic mouse heart demonstrated a marked increase in the expression of miR-126 from the early stages of diabetes (1.53 ± 0.13 fold at 8 weeks of age and 1.89 ± 0.13 fold at 12 weeks of age) ( Figure 3B , P < 0.001 and P < 0.0001 vs. non-diabetic at 8 weeks and 12 weeks, respectively) and a 2.21 ± 0.09 fold increase in miR-132 at 8 weeks of age ( Figure 3B , P < 0.0001 vs. non-diabetic of corresponding age group). This was in line with the expression level of miRs in human plasma showing a marked up-regulation of miR-126 expression from the early stages of diabetes ( Figure 3A) . However, starting from 16 weeks of age, there was a consistent down-regulation of both miRs in diabetic heart ( Figure 3B ). While the exact reason for the initial increase in the expression level of angiomiRs in the diabetic heart is not clear, previous studies by our group 6, 7 and others 20 has shown an initial activation of pro-survival factors in the diabetic heart, which could be attributed to the onset of compensatory mechanisms in the event of acute diabetic stress. Importantly, the first significant decrease in the number of capillary and smaller arterioles (< 50 mm) in the diabetic mouse heart was only observed at 20 weeks of age (Figures 3C-D and Supplementary ma terial online, Figure S2 ), thereby confirming that the dysregulation of angiomiRs precedes the development of microangiopathy in the diabetic heart. Further, similar to the human myocardium, diabetes markedly increased the number of TUNEL-positive capillaries from 20 weeks of age ( Figure 3E ).
Altered expression of target proteins in the diabetic heart
Having confirmed the dysregulated expression of miR-126 and miR-132, our next aim was to establish a causative link between the down-regulation of angiomiRs and the development of microangiopathy in the diabetic heart. To understand the mechanisms by which miR-126 and miR-132 regulate endothelial biology, potential mRNA targets were searched using available target prediction algorithms (miRanda, DIANA Lab, and TargetScan) and publications. These searches identified Sprouty-related, EVH1 domain-containing protein 1 (Spred1), a known inhibitor of vascular endothelial growth factor (VEGF) and RASA1 or p120RasGAP (an antiangiogenic protein) as the direct targets for miR-126 and miR-132, respectively. 17, 21, 22 Alignment of 3'-UTR of the target mRNA among mouse and human species revealed that the predicted binding sites for miR-126 and miR-132 were highly conserved across species, suggesting the potential regulation of these proteins by angiomiRs in both human and mouse hearts (Supplementary material online, Figure S3A-D) . Using a Luciferase reporter assay, we confirmed Spred1 and p120RasGAP as the direct targets for miR-126 and miR-132, respectively ( Figure 4A) . Further, the diabetic human heart showed a significant decrease in the expression of proangiogenic VEGF ( Figure 4B ) and increased expression of antiangiogenic Spred1 ( Figure 4C ) and p120RasGAP ( Figure 4D ). Gene expression analysis of the diabetic mouse heart at different time points demonstrated a direct correlation between miR-126 ( Figure 3B ) and VEGF mRNA levels ( Figure 4E ) and an inverse correlation between miR-126 and miR-132 ( Figure 3B ) expression profiles with Spred1 ( Figure 4F ) and p120RasGAP ( Figure 4G ) mRNA levels, respectively. Gene expression analysis was not performed after 20 weeks of age because there was no significant difference in the miR expression profile between 20 and 32 weeks of age ( Figure 3B ).
To determine the functional efficacy of the modulated target genes, we performed a western blot analysis on VEGF and p120RasGAP in both human and mouse hearts. Although VEGF is not the direct target for miR-126, its expression is indirectly controlled by miR-126 through Spred1, a negative regulator of VEGF. 21, 23 Moreover, our recent study confirmed that the altered expression of VEGF in the human diabetic heart corresponded to the down-regulation of miR-126. 24 In the current study, the human diabetic heart showed a marked activation of the expression level of antiangiogenic p120RasGAP, a direct target of miR-132 (P < 0.001 vs. both ND-IHD and ND-H, Figure 5A and Supplementary material online, Figure S4A ). Due to the limitation in the amount of LV tissue available for analysis, western blot analysis was restricted to RAA samples. Western blot analysis of the diabetic mouse heart showed marked down-regulation of VEGF starting from 12 weeks of age (P < 0.01, Figure  5B and Supplementary material online, Figure S4B ) until the end of the study. p120RasGAP protein was up-regulated in the diabetic heart at all time points starting from 12 weeks of age ( Figure 5C and Supplementary material online, Figure S4C) ; it exhibited an inverse correlation with the miR-132 expression pattern ( Figure 3B) . Interestingly, in the non-diabetic heart, VEGF showed a consistent increase with aging ( Figure 5B and Supplementary material online, Figure S4B ), although the exact reason for this increase is not known.
Restoration of angiomiRs improves the function of aortic rings ex vivo and HUVECs in vitro
Our final objective was to determine whether therapeutic restoration of angiomiRs prevents/reduces the deleterious effects of diabetes in HUVECs. To determine the optimal condition to simulate the diabetic Figure 6A ) of HG exposure. These findings were consistent with the results from the diabetic mouse heart, which showed an initial up-regulation of both miRs followed by a consistent decrease with the evolution of the disease ( Figures 3A and B) . Further, HUVECs exposed to HG showed a significant increase in caspase-3/7 activity at 48 h and 72 h of HG exposure ( Figure 6B ), corresponding to the down-regulation of both angiomiRs ( Figure 6A ). Based on these observations, a 48 h time point was chosen for further experiments.
To validate the molecular and functional changes in HG-exposed HUVECs, we measured the expression of VEGF, Spred1, and p120RasGAP after 48 h of HG treatment. Consistent with our findings in the human and mouse hearts (Figure 4) , quantitative RT-PCR analysis showed a significant down-regulation of VEGF (Supplementary material online, Figure S5A ), whereas we observed an up-regulation of Spred1 (Supplementary material online, Figure S5B ) and p120RasGAP
(Supplementary material online, Figure S5C ) in HG-treated HUVECs. Furthermore, functional analysis confirmed significant impairment in the outgrowth of endothelial sprouts from the aortic rings collected from diabetic mice compared to those collected from their non-diabetic littermates ( Figure 6C) . We also observed significant impairment in tube formation (Supplementary material online, Figure S6 ), cell proliferation ( Figure 6D) , and migration ( Figure 6E ) in HG-treated HUVECs. Interestingly, the overexpression of miR-126 and miR-132 restored all of the impaired function in diabetic aortic rings and HG-treated HUVECs ( Figures 6C-E and Supplementary material online, Figures S5 and S7) , confirming the importance of both angiomiRs in HG-mediated endothelial cell dysfunction. It is worth noting that miR-126 was superior in augmenting tube formation (Figures 6Cii-iii) and cell proliferation ( Figure 6D) , whereas miR-132 was superior in improving the migration ( Figure 6E ) capability of HG-treated HUVECs under HG; the combination therapy was superior in attenuating apoptotic cell death ( Figure 6F) . Together, these findings suggest an orchestrated role of both angiomiRs in regulating angiogenic processes in the endothelium by controlling the gene expression of important factors involved in this dynamic process.
The final question that remained was whether the molecular and functional impairments were directly due to the down-regulation of miR-126 and miR-132. To answer this, we carried out loss-of-function experiments by inhibiting the activity of angiomiRs in NG-cultured HUVECs using antimiR-126 and anti-miR-132. Inhibition of angiomiRs significantly reduced the levels of proangiogenic factor VEGF ( Figure 7A ) while increasing the expression of antiangiogenic factors Spred1 ( Figure 7B ) and p120RasGAP ( Figure  7C ). In addition, inhibition of angiomiRs also reduced the outgrowth of endothelial sprouts from the aortic rings collected from non-diabetic mice ( Figure 7D ) and demonstrated reduced tube formation (Supplementary ma terial online, Figure S8 ) and cell proliferation ( Figure 7E ) while increasing the caspase-3/7 activity ( Figure 7F ) in HUVECs. Importantly, anti-miR-treated HUVECs were phenotypically similar to those cultured under HG conditions. These data confirm that the dysregulation of miR-126 and miR-132 are the major causes of HG-induced endothelial cell dysfunction.
Discussion
Microangiopathy in the heart is one of the major contributing factors in the development of DHD, which is characterized by myocardial dilatation, cardiac hypertrophy, and early diastolic and late systolic defects. 26 MiR-126 and miR-132 are endothelial-specific miRs and are considered to be angiomiRs due to their ability to induce angiogenesis in the endothelial cells by regulating the expression of proangiogenic and antiangiogenic factors at the post-transcriptional level. 17, 21, 22 To the best of our knowledge, this is the first study demonstrating the dysregulation of miR-126 and miR-132 (angiomiRs) in the heart from the early stages of diabetes. While a significant study by Zampetaki et al. 27 showed the loss of circulating levels of miR-126 in people with type 2 diabetes, we now demonstrate that the reduced circulating levels of angiomiRs can be detected in the early stages of type 2 diabetes. This is supported by the marked dysregulation in the expression pattern of both miRs in type 2 diabetic mice hearts from the early stages of the disease, preceding the onset of microangiopathy. We further demonstrate the molecular pathways establishing a link between the dysregulation of angiomiRs and the development of microangiopathy in the heart. Finally, our proof-ofconcept in vitro study using cultured endothelial cells underpins the potential therapeutic role of angiomiRs in correcting microangiopathy in the diabetic heart by promoting angiogenesis and the survival of endothelial cells. Although the existence of microangiopathy in the diabetic heart is well established, the mechanisms underpinning this alteration and especially the basis for differences in outcomes between diabetic and nondiabetic IHD following any acute injury are still unknown. Several studies have demonstrated reduced myocardial expression of angiogenic growth factors such as VEGF, TGFb, HIF-1a, and iNOS as well as lower levels of prosurvival proteins like pAkt in the diabetic myocardium as the secondary mediators for microvascular rarefaction. 1, 5, 28 Our results provide a new causal link between the decreased levels of angiomiRs and cardiac microangiopathy, suggesting that reductions in the level of miR-126 and miR-132 could be the primary regulators of microangiopathy in the diabetic heart. miR-126 is largely expressed in endothelial cells and plays a key role in governing vascular integrity and angiogenesis. 23, 24, 27 It facilitates VEGF signalling by repressing the major negative regulator of the VEGF pathway, Spred1. 29 The miR-126-VEGFR2 axis has been confirmed as a central regulator for the processes of angiogenesis as well as endothelial cell proliferation, differentiation, and survival. 30 In our study, the diabetic heart demonstrated down-regulation of proangiogenic VEGF and the up-regulation of antiangiogenic Spred1. MiR-132 is another proangiogenic miR that is highly expressed in endothelial cells. 9, 17 Upon VEGF stimulation, miR-132 has been shown to be rapidly transcribed by cAMP response element binding protein (CREB) to suppress endothelial p120RasGAP, activating angiogenesis. 17 Our previous study demonstrated the key role of miR-132 in mediating the therapeutic efficacy of adult human pericyte progenitor cells. 6 In the current study, we observed an initial decrease in p120RasGAP parallel to an increase in miR-132; however, with the progression of the disease and the down-regulation of both angiomiRs, there was a consequent upregulation of p120RasGAP in the diabetic heart. Moreover, since miR-126 indirectly regulates the expression of VEGF, which is a potent activator of miR-132, it is plausible that miR-126 is a key regulator of miR-132. This notion is further supported by a marked up-regulation of miR-132 following miR-126 overexpression, whereas miR-132 overexpression did not have any effect on miR-126 (Supplementary material online, Figure S5 ). Of note, the alteration in the expression of both angiomiRs preceded the changes in the target proteins or development of any detectable structural alterations in the myocardium, suggesting that angiomiRs are early modulators of cardiac microangiopathy in the diabetic myocardium.
One intriguing aspect of our study is the initial increase in VEGF and the decrease in p120RasGAP corresponding to an increase in miR-126 and miR-132 at 8 and 12 weeks of age in the diabetic mouse heart. While the exact mechanism for this is not clear, it may be attributed to the activation of compensatory mechanisms under acute diabetic stress. 31 One such mechanism is the increase in prosurvival kinase AKT, which has been demonstrated to be activated by an miR-126-dependent increase in VEGF. 29, 30 This is further supported by our previous study showing an up-regulation of pAKT in the diabetic heart at an initial stage of diabetes followed by a progressive decline with the evolution of the disease. 15 Recent studies 3, 9, 15 and this study clearly show that cardiovascular complications (molecular alterations) in the diabetic heart develop at a much earlier stage than can be clinically diagnosed. This suggests that any interventions to halt or reverse these changes should be considered early on after the diagnosis of diabetes, especially given that the disease has usually been present for many years prior to diagnosis. 32 We have examined dysregulation of the circulating level of angiomiRs in people with type 2 diabetes without any history of CVD, finding that in type 2 diabetic mice, this dysregulation occurs early and correlates with the development of microangiopathy through the activation of endothelial cell death. These findings suggest that these circulating angiomiRs could be a clinically useful biomarker for the early detection of microangiopathy in the diabetic heart. expression levels. This network produces a homeostatic loop of miR-126-VEGF-miR-132 expression levels which regulates angiogenesis and cell survival in endothelial cells. However, under diabetic stress (B), this homeostatic network gets tampered due to the down-regulation of angiomiRs, miR-126 and miR-132 which consequently leads to impaired angiogenesis, reduced endothelial cell proliferation, migration and survival.
